Mochida Pharmaceutical Co., Ltd. (JP:4534)
:4534
Want to see JP:4534 full AI Analyst Report?
4534 Stock Chart & Stats
¥3615.00
-¥40.00(-1.17%)
At close: 4:00 PM EST
¥3615.00
-¥40.00(-1.17%)
Day’s Range― - ―
52-Week Range¥2,859.00 - ¥3,965.00
Previous CloseN/A
Volume18.00K
Average Volume (3M)34.37K
Market Cap
¥113.49B
Enterprise Value¥91.63B
Total Cash (Recent Filing)¥54.69B
Total Debt (Recent Filing)¥830.00M
Price to Earnings (P/E)12.6
Beta0.66
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.34%
Share Statistics
EPS (TTM)169.96
Shares Outstanding36,390,000
10 Day Avg. Volume38,620
30 Day Avg. Volume34,366
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)0.86
Price to Sales (P/S)1.07
P/FCF Ratio15.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.3
Revenue Forecast (FY)¥110.00B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetMochida's minimal leverage and robust equity ratio provide durable financial flexibility. This balance sheet strength supports multi-year R&D and licensing investments, absorbs reimbursement or regulatory shocks, and reduces refinancing risk, enabling strategic choices over a 2–6 month horizon and beyond.
Healthy Gross And Net Profit MarginsSustained gross and net margins reflect enduring operational efficiency and pricing power in specialty niches. Strong margins fund internal investment, help sustain dividends and R&D even if top-line growth slows, and provide a buffer that supports the company’s strategic execution over medium term horizons.
Specialized Therapeutic Focus And Sales NetworkConcentration on dermatology and gynecology with an established MR-driven sales channel creates durable commercial advantages: deep physician relationships, tailored marketing, and capability to in-license and commercialize niche products domestically, supporting steady prescription revenue and product rollouts.
Bears Say
Declining Revenue Growth TrendA persistent decline in revenue growth is structurally worrying: it reduces economies of scale, limits internal funding for new drug development or licensing, and may signal product lifecycle challenges or market saturation in core areas, constraining medium‑term growth prospects.
Volatile Free Cash Flow GrowthVolatile free cash flow undermines predictable funding for R&D, launches, and partner deals. Even with low debt, irregular FCF increases reliance on external financing for strategic actions, complicates capital allocation, and raises execution risk for multi-quarter product or commercial initiatives.
Concentration In Domestic Japanese MarketHeavy reliance on Japan exposes the company to country‑specific reimbursement, regulatory shifts, and demographic maturity. Limited geographic diversification constrains addressable market growth and makes medium-term revenue expansion dependent on domestic policy and sales execution rather than broader international opportunity.
Mochida Pharmaceutical Co., Ltd. News
4534 FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was ¥2859.00 and its highest was ¥3965.00 in the past 12 months.
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
Mochida Pharmaceutical Co., Ltd.’s market cap is ¥113.49B.
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is Jul 31, 2026 which is in 77 days.
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Mochida Pharmaceutical Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥44.05 earnings per share for the quarter, beating the consensus estimate of N/A by ¥44.05.
Is Mochida Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
Mochida Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥40 which represents an annual dividend yield of 2.34%. See more information on Mochida Pharmaceutical Co., Ltd. dividends here
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Mochida Pharmaceutical Co., Ltd. reported an EPS of ¥44.05 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.537%.
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4534
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Options Prices
Currently, No data available
---